Reading NBIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NBIX free→Reading NBIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NBIX free→QuarterlyIQ Insights · NBIX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing discusses an equity plan amendment, not a management change.
Regulation FD Disclosure. On May 18, 2026, the Company issued a press release announcing the closing of the Merger, a copy of which is attached as Exhibit 99.1 to this Report and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section and will not be incorp…
Entry into a Material Definitive Agreement. The information set forth in
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On May 14, 2026 (the “ Closing Date ”), the Company entered into a credit agreement (the “ Credit Agreement ”) with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (in such capacities, the “ Agent ”), and the lenders party thereto. The Credit Agreement provides for a five-year, $1.0 billion senior secured revolving credit facility (the “ Revolving Credit F…
The Offer and related withdrawal rights expired as scheduled at one minute following 11:59 p.m. Eastern time on May 15, 2026 (such date and time, the “ Expiration Date ”). Purchaser was advised by Equiniti Trust Company, LLC, the depositary for the Offer, that as of the Expiration Date, a total of 46,356,114 Soleno Shares had been validly tendered (and not validly withdrawn) pursuant to the Offer, representing approximately 88.9% of the issued and outstanding Soleno Shares as of the Expiratio…
Results of Operations and Financial Condition. On May 5, 2026, Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.